Concepedia

Publication | Open Access

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age

DOIFull Paper Access

96

Citations

18

References

2023

Year

Flor M. Muñoz, Lawrence Sher, Charu Sabharwal, Alejandra Gurtman, Xia Xu, Nicholas Kitchin, Stephen Lockhart, Robert Riesenberg, Joanna M Sexter, Hanna Czajka,
New England Journal of Medicine

Abstract

A three-dose primary series of 3-μg BNT162b2 was safe, immunogenic, and efficacious in children 6 months to 4 years of age. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.).

References

YearCitations

Page 1